Cochlear (ASX:COH) and Telix (ASX:TLX) have issued updates clarifying that they do not expect an impact from the US Government's decision to apply a 10 per cent tariff to Australian imports.
While pharmaceuticals were formally excluded from tariffs, the impact on devices and other health products was less clear.
In a statement, Cochlear said "that it will continue to be able to rely on a chapter of the Harmonized Tariff Schedule of the United States that provides for duty-free importation on a range of products into the US, including hearing implants."
The company added, "Cochlear will continue to actively monitor and engage in the evolving global landscape so that it can continue to provide implantable hearing solutions to as many people as possible, and service existing recipients over the course of their life."
Telix also said that it does not expect any material impact on its business or supply chain as a result of the tariffs.
"Telix has an extensive US-based manufacturing and distribution infrastructure, including third-party manufacturing sites and radiopharmacy partner networks, for the production and delivery of its FDA - approved products Illuccix and Gozellix," said the company.
Telix also acknowledged reports of significant change at the FDA," including job cuts. "Despite this, the agency continues to process applications and information requests. Telix has not been notified of any changes to the timelines for its New Drug Application for Pixclara (TLX101-CDx) or Biologics License Application for Zircaix (TLX250-CDx)," it said.